-
公开(公告)号：US20240115819A1
公开(公告)日：2024-04-11
申请号：US18538917
申请日：2023-12-13
CPC分类号： A61M15/08 , A61M11/02 , A61M15/009 , A61M2210/0618
摘要： A delivery device for a compound including: a housing, vial holding a compound; and a source of propellant, wherein the housing provides an inlet and an outlet for the vial, wherein the inlet is in fluid communication with the source of propellant and is directed against the compound and the outlet allows for delivery of the compound.
-
2.发明公开公开(公告)号：US20230301955A1
公开(公告)日：2023-09-28
申请号：US18313330
申请日：2023-05-06
发明人： John D. Hoekman , Kelsey H. Satterly , Inna Dashevsky , Aditya R. Das , Stephen B. Shrewsbury , Gregory J. Davies , Bhavin Y. Gajera
IPC分类号： A61K31/198 , A61P25/16 , A61K9/00 , A61M15/00 , A61M11/02 , A61M15/08 , A61K9/16 , A61K31/165 , A61K9/48 , A61K9/14
CPC分类号： A61K31/198 , A61P25/16 , A61K9/0075 , A61M15/0036 , A61M11/02 , A61M15/003 , A61M15/08 , A61M15/0035 , A61K9/0043 , A61K9/1623 , A61K9/1652 , A61K31/165 , A61K9/48 , A61K9/14 , A61K9/0053 , A61M15/009 , A61M2202/04 , A61M2202/064 , A61M2206/20 , A61M2205/8225
摘要： A dry pharmaceutical composition is provided that is suitable for respiratory tract delivery of levodopa and DDI for treatment of Parkinson's disease or Parkinson syndrome. The dry pharmaceutical composition comprises levodopa, a dopa decarboxylase inhibitor (DDI) and at least one excipient. A unit dosage form of the dry pharmaceutical composition and a method of treating a patient with Parkinson's disease or Parkinson syndrome by administering the dry pharmaceutical composition are also provided.
-
公开(公告)号：US11759585B2
公开(公告)日：2023-09-19
申请号：US17420640
申请日：2019-12-17
CPC分类号： A61M15/08 , A61M11/02 , A61M15/007 , A61M15/009
摘要： A nasal drug delivery device for delivering a plume derived from a propellant and a drug compound. The drug compound is in an intranasal dosage form in the form of powder, suspension, dispersion, or liquid. The propelled intranasal dosage form is deposited within the upper nasal cavity such as the olfactory region. The drug deposited within the olfactory region is delivered to the brain avoiding the blood-brain-barrier. Hydrofluoroalkane propellant from a pressurized canister is channeled to a diffuser and drug-containing channel where the intranasal dosage form is aerosolized. The aerosolized intranasal dosage form passes through a nozzle thus delivering a plume to the user's upper nasal cavity.
-
公开(公告)号：US20230241334A1
公开(公告)日：2023-08-03
申请号：US18297601
申请日：2023-04-08
CPC分类号： A61M15/08 , A61M15/009 , A61M11/02 , A61M2210/0618
摘要： A delivery device for a compound including: a housing, vial holding a compound; and a source of propellant, wherein the housing provides an inlet and an outlet for the vial, wherein the inlet is in fluid communication with the source of propellant and is directed against the compound and the outlet allows for delivery of the compound.
-
公开(公告)号：US11690819B2
公开(公告)日：2023-07-04
申请号：US17682033
申请日：2022-02-28
发明人： John D. Hoekman , Kelsey H. Satterly , Inna Dashevsky , Aditya R. Das , Stephen B. Shrewsbury , Gregory J. Davies , Bhavin Y. Gajera
IPC分类号： A61K31/198 , A61K9/00 , A61K9/14 , A61K9/16 , A61K9/48 , A61K31/165 , A61M11/02 , A61M15/00 , A61M15/08 , A61P25/16
CPC分类号： A61K31/198 , A61K9/0043 , A61K9/0053 , A61K9/0075 , A61K9/14 , A61K9/1623 , A61K9/1652 , A61K9/48 , A61K31/165 , A61M11/02 , A61M15/003 , A61M15/0035 , A61M15/0036 , A61M15/08 , A61P25/16 , A61M15/009 , A61M2202/04 , A61M2202/064 , A61M2205/8225 , A61M2206/20
摘要： A dry pharmaceutical composition is provided that is suitable for respiratory tract delivery of levodopa and DDI for treatment of Parkinson's disease or Parkinson syndrome. The dry pharmaceutical composition comprises levodopa, a dopa decarboxylase inhibitor (DDI) and at least one excipient. A unit dosage form of the dry pharmaceutical composition and a method of treating a patient with Parkinson's disease or Parkinson syndrome by administering the dry pharmaceutical composition are also provided.
-
公开(公告)号：US20220296504A1
公开(公告)日：2022-09-22
申请号：US17498381
申请日：2021-10-11
IPC分类号： A61K9/00 , A61P25/16 , A61M15/00 , A61K31/198 , A61K9/16 , A61K31/197
摘要： Methods are provided for treating OFF episodes in a patient with Parkinson's disease or a Parkinson syndrome, comprising administering to a subject with Parkinson's disease or a Parkinson syndrome experiencing an OFF episode an effective dose of a dry pharmaceutical composition comprising L-DOPA, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma levodopa concentration (Cmax) of at least 200 ng/mL, with (b) a mean time to Cmax (Tmax) of levodopa of less than or equal to 60 minutes. Dry pharmaceutical compositions of levodopa suitable for intranasal administration and unit dosage forms comprising the dry pharmaceutical compositions are also provided.
-
公开(公告)号：US11878109B2
公开(公告)日：2024-01-23
申请号：US16875906
申请日：2020-05-15
CPC分类号： A61M11/02 , A61M15/0065 , A61M2210/0618
摘要： Embodiments relate to a single-use device for delivery of medication into a nasal cavity. In an embodiment, the device includes a propellant canister containing a propellant capable of propelling the compound to the nasal cavity. The propellant canister is displaceable between an unactuated position and an actuated position within the device. The device further includes an actuation element with an actuation lever configured to displace the propellant canister from the unactuated position to the actuated position. The device also includes a puncture element positioned to puncture the propellant canister, which causes the release of the propellant from the propellant canister. The device further includes a dose holding chamber containing a unit dose of the compound. The dose holding chamber is positioned such that propellant flows into the dose holding chamber and causes the compound to be propelled from the dose holding chamber to the nasal cavity of the user.
-
公开(公告)号：US11752100B2
公开(公告)日：2023-09-12
申请号：US17574511
申请日：2022-01-12
CPC分类号： A61K9/0043 , A61K9/16 , A61K9/1617 , A61K9/1623 , A61K9/1652 , A61K31/00 , A61K31/5513 , A61M15/003 , A61P25/18
摘要： Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (Cmax) of at least 30 ng/mL, with (b) a mean time to Cmax (Tmax) of olanzapine of less than 0.5 hours. Dry pharmaceutical compositions and devices suitable for intranasal delivery of olanzapine are provided.
-
公开(公告)号：US11730903B2
公开(公告)日：2023-08-22
申请号：US16664588
申请日：2019-10-25
CPC分类号： A61M15/08 , A61M11/02 , A61M2202/0468 , A61M2202/064 , A61M2205/073 , A61M2205/8225
摘要： A compound delivery device for delivering a plume derived from a propellant and a drug formulation. The drug formulation is in an intranasal dosage form in the form of powder, suspension, dispersion or liquid. The propelled intranasal dosage form is deposited within the olfactory region of the nasal cavity. The drug deposited within the olfactory region is delivered to the brain avoiding the blood-brain-barrier. Hydrofluoroalkane propellant from a pressurized canister is channeled to a diffuser and drug-containing chamber where the intra-nasal dosage form is aerosolized. The aerosolized intra-nasal dosage form passes through a nozzle thus delivering a plume to the olfactory region of a user's nasal cavity.
-
10.发明授权公开(公告)号：US11517548B2
公开(公告)日：2022-12-06
申请号：US16517423
申请日：2019-07-19
发明人： John D. Hoekman , Kelsey H. Satterly , Inna Dashevsky , Aditya R. Das , Stephen B. Shrewsbury , Gregory J. Davies , Bhavin Y. Gajera
IPC分类号： A61K31/198 , A61K9/00 , A61K9/14 , A61K9/16 , A61K9/48 , A61K31/165 , A61M11/02 , A61M15/00 , A61M15/08 , A61P25/16
摘要： A dry pharmaceutical composition is provided that is suitable for respiratory tract delivery of levodopa and DDI for treatment of Parkinson's disease or Parkinson syndrome. The dry pharmaceutical composition comprises levodopa, a dopa decarboxylase inhibitor (DDI) and at least one excipient. A unit dosage form of the dry pharmaceutical composition and a method of treating a patient with Parkinson's disease or Parkinson syndrome by administering the dry pharmaceutical composition are also provided.
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.02 秒)
